Suchergebnisse - "Rizvi, Hira"

PubPharm (70)

51

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer

enthalten in: JCO precision oncology | 2019

von Vokes, N. | Liu, D. | Ricciuti, B. | +19

52

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Tio, M. | Rai, R. | Ezeoke, O. | +22

53

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Arbour, K. | Mezquita, L. | Long, N. | +16

CommentIn: Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S364-S368. - PMID 32038916

54

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

enthalten in: Cancer immunology research | 2018

von Santini, F. | Rizvi, H. | Plodkowski, A. | +11

55

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

enthalten in: Cancer discovery | 2018

von Skoulidis, F. | Goldberg, M. | Greenawalt, D. | +66

CommentIn: Cancer Discov. 2018 Jul;8(7):794-796. - PMID 29967073

56

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Leonardi, G. | Gainor, J. | Altan, M. | +8

57

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

enthalten in: Cancer cell | 2018

von Hellmann, M. | Nathanson, T. | Rizvi, H. | +29

CommentIn: Nat Rev Clin Oncol. 2018 Jul;15(7):403. - PMID 29703915

58

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors

enthalten in: Gynecologic oncology reports | 2018

von Martin, M. | Sabari, J. | Turashvili, G. | +4

59

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Rizvi, H. | Sanchez-Vega, F. | La, K. | +29

CommentIn: J Clin Oncol. 2018 Mar 1;36(7):631-632. - PMID 29337637

60

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

enthalten in: Science (New York, N.Y.) | 2018

von Routy, B. | Le Chatelier, E. | Derosa, L. | +45

CommentIn: Nat Rev Clin Oncol. 2018 Jan;15(1):6-7. - PMID 29158588